Eisai Co., Ltd. (4523) Earnings Call Transcripts

Eisai Co., Ltd.'s Latest Earnings Call - May 25, 2026

Eisai Co., Ltd. reported strong growth in its fiscal year 2025 results, driven primarily by the success of LEQEMBI, which saw revenue nearly double year-over-year. For fiscal year 2028, management targets consolidated revenue of JPY 1 trillion and core operating profit of JPY 90 billion, reflecting a strategic focus on sustainable growth through its three core products: LEQEMBI, LENVIMA, and DAYVIGO. The company has maintained its guidance, with no significant changes, indicating confidence in its growth trajectory.

Reported metrics

Guidance from management

Eisai maintains its fiscal year 2028 targets of JPY 1 trillion in revenue and JPY 90 billion in core operating profit, indicating confidence in its growth strategy and pipeline developments.

What management said

[Interpreted] Thank you very much for your question. As has been mentioned, we are focusing on the neurology and oncology areas. And regarding this first for oncology, which will continue to be our focus area. And later-stage development or assets close to be approved, yes, these are the focus areas. And R&D before POC asset also included in consideration in order to enhance the solid pipeline. We will follow-up on t...

[Interpreted] Thank you for your question. JPY 1 trillion and JPY 90 billion target were determined based on recent conditions, including progress in LEQEMBI and reimbursement status in Europe. As we discussed in earnings presentation session in Europe, we are -- we have developed more conservative plan for the next fiscal year. And based on that, we have reviewed the plans. In the past, in comparison to what you h...

What analysts pressed on

Analysts raised concerns about the sustainability of profitability given the increased R&D investments and potential competition in the market. There were questions regarding the impact of rising costs and the effectiveness of cost management strategies.

Main topics on the call

• Revenue Growth from LEQEMBI — LEQEMBI's revenue for fiscal year 2025 was approximately JPY 88 billion, with projections to reach JPY 300 billion by fiscal year 2028. Management stated, "LEQEMBI grew steadily across all regions, achieving full year re...
• Core Operating Profit Guidance — Eisai aims for a core operating profit of JPY 90 billion by fiscal year 2028, indicating a focus on enhancing profitability. The CFO noted, "Our FY 2028 targets do not include onetime gains," emphasizing sustainable grow...
• Investment in R&D and Pipeline — Eisai plans to invest JPY 500 billion in R&D over the next three years, focusing on neurology and oncology. The COO highlighted, "We will continue to invest in our priority pipeline while strengthening our management bas...
• Cost Management Strategies — Management acknowledged rising costs due to product mix changes but emphasized efforts to control expenses. The CFO stated, "We will mitigate the increase through cost reduction measures centered on LEQEMBI."

Read the full Eisai Co., Ltd. transcript (May 25, 2026) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 37 Eisai Co., Ltd. earnings call transcripts on record, spanning January 31, 2020 to August 3, 2026. Based on this history, Eisai Co., Ltd. reports quarterly. The most recent call on file is dated August 3, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

4523

Exchange

TSE

Country

JP

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

37

First call

January 31, 2020

Most recent

August 3, 2026

Reporting cadence

quarterly